Tumor Bone Diseases: Molecular Mechanisms and Opportunities for Novel Treatments

Authors: Susa M.; Glatt M.; Teti A.

Source: Current Medicinal Chemistry - Anti-Cancer Agents, Volume 1, Number 3, November 2001 , pp. 313-329(18)

Publisher: Bentham Science Publishers

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

A variety of cancers are associated with bone. Primary tumors can arise in bone, common cancers, such as those of breast and prostate origin, metastasize to bone, and multiple myeloma neoplastic disease affects bone profoundly. The cellular and molecular mechanisms underlying these pathological processes are increasingly being understood. The interaction of tumor cells with bone cells, osteoblasts and osteoclasts, and with the bone local environment is a new promising direction in research, which should help to develop new therapies. In this article we will relate the newest developments in the molecular research to the pathology of the tumor bone disease. Potential new targets for drugs, aimed specifically at tumor bone diseases, will be highlighted. Furthermore, we will describe the existing compounds that are either used in treatment or have a potential as therapeutic agents, such as bisphosphonates, Src inhibitors, and selective estrogen receptor modulators.

Keywords: Tumor Bone Diseases; Bisphosphonates; Src inhibitors; Protein kinase; Protease; Geranylgeranyl transferase; Nuclear; VEGF; Matrix metalloproteinases (MMPs); Receptors

Language: English

Document Type: Review article

DOI: 10.2174/1568011013354589

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy